Getting the diagnosis right in NHL: role of immunohistochemistry and molecular diagnostic testing

Julie Teruya-Feldstein1

  • 1Immunohistochemistry Laboratory, Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. feldstej@mskcc.org

Insights

Diagnosing lymphoid neoplasms requires integrating clinical, morphologic, and molecular data. Advanced immunophenotyping and molecular diagnostics improve accuracy for better patient management and targeted therapies.

Area of Science:

  • Hematopathology
  • Oncology
  • Molecular Diagnostics

Background:

  • Lymphoid neoplasms present diagnostic challenges due to heterogeneity, with over 40 distinct diseases.
  • Accurate diagnosis is crucial for patient management and the development of targeted therapies.

Purpose of the Study:

  • To review recent immunophenotypic and molecular diagnostic studies for lymphoid neoplasms.
  • To highlight the integration of various diagnostic modalities for precise lymphoma diagnosis.

Main Methods:

  • Review of published immunophenotypic and molecular diagnostic studies.
  • Analysis of Society of Hematopathology and European Association for Haematopathology Workshop summaries.
  • Integration of clinical, morphologic, immunohistochemical, cytogenetic, and molecular data.

Main Results:

  • Immunophenotyping and molecular diagnostics significantly contribute to precise lymphoid neoplasm diagnoses.
  • Understanding disease complexity through research collaborations aids in prognostic information and therapy development.

Conclusions:

  • Precise lymphoma diagnosis necessitates integrating diverse data: clinical, morphologic, immunohistochemical, cytogenetic, and molecular.
  • Accurate identification of specific diseases informs prognosis and guides therapeutic strategies.